Freenome aims to take on the big beasts
Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.
Pacbio is in it for the long run
The sequencing sector is changing fast, but Pacbio believes its technology can hold out against its rivals.
Device makers buy big
Whether sitting on a pile of cash or guarding against growing pressures, acquisitions are the answer.
The heat is on for Oxford Nanopore
Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.
Medtech gears up for a vintage acquisition year
Device deal making is back in a big way, despite the munificence of venture funds.
